Phaseline

Targets › COL3A1

COL3A1 (Collagen alpha-1(III) chain): drug programs, companies and trials

3 programs from 3 companies in 8 trials: 5 Phase 4, 1 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Genitourinary, Other; next expected readout Dec 2027.

Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. (UniProt, P02461)

Open in Phaseline: the race on COL3A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Endo USA Inc., a Keenova Therapeutics CompanyCollagenase Clostridium Histolyticum (KN3835)
Collagen hydrolytic enzyme
COL1A2, COL1A1, COL2A1, COL3A1, COL4A1Phase 3Flexible Hammertoe; Peyronie Disease; Peyronie's Disease; Dupuytren Disease of Finger …Dec 2027
Wang JianliuRecombinant Humanized Type III Collagen Lyophilized Fibers
Intrauterine injection of recombinant humanized type III collagen to promote endometrial r
COL3A1Phase 2Atypical Endometrial HyperplasiaDec 2027
Peking University People's HospitalRecombinant Humanized Type III Collagen (rhCOL3)
Type III Collagen - tissue protective factor and tumor microenvironment remodeler
COL3A1Phase 1Breast CancerDec 2028

Conditions

Peyronie Disease (2) Breast Cancer (1) Flexible Hammertoe (1) Peyronie's Disease (1) Dupuytren Disease of Finger (1) Dupuytren Contracture (1) Atypical Endometrial Hyperplasia (1)

Modalities

protein or peptide (2), small molecule (1)

Companies

Peking University People's Hospital (1) Endo USA Inc., a Keenova Therapeutics Company (1) Wang Jianliu (1)

Related targets

COL1A2 (1) COL1A1 (1) COL2A1 (1) COL4A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.